The Desmoid Tumor Research Foundation

May 2021

What is the best front-line approach in patients with desmoid fibromatosis? – A retrospective analysis from a reference center

Author Information

Sobczuk P (1), Agnieszczak I (2), Grycuk W (2), Czarnecka A (3), ?witaj T (4), Kose?a-Paterczyk H (4), Morysi?ski T (4), Zdzienicki M (4), Rutkowski P (4)

(1)Dept of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Dept of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical Univ of Warsaw, Warsaw, Poland. (2)Dept of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Faculty of Medicine, Medical Univ of Warsaw, Poland. (3)Dept of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Dept of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland. (4)Dept of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Publication

Eur J Surg Oncol

Summary

Desmoid fibromatosis (DF) is a locally aggressive, not metastasizing tumor associated with high local recurrence rates. Surgery was a standard-of-care for DF treatment; however, recently, conservative treatment and active surveillance are preferred. This study aimed to evaluate the real-life outcomes of DF treatment.

View Abstract